GLP-1 Medications and Muscle Loss: What Strength Coaches Need to Know

The Context: Why This Matters Now

GLP-1 receptor agonists, semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound), are now the most widely prescribed medications for weight management in history. In the UK, the NHS began rolling out semaglutide through specialist weight management services in 2023, and private prescribing has grown substantially since. NASM's 2026 fitness trends report identified GLP-1 medications as one of the most significant disruptive forces reshaping personal training: specifically noting that widespread use has fundamentally changed the nature of weight-loss coaching, elevating the role of muscle preservation, strength training, and metabolic support rather than calorie-burn-centric approaches. If you coach general population clients, some of them are already using these medications. Many more will be. The question is not whether this affects your work, it does, but whether you understand the physiology well enough to coach around it effectively.

What Actually Happens to Muscle on GLP-1 Therapy

The concern about muscle loss on GLP-1 medications is legitimate but frequently overstated in both directions: catastrophised by critics and minimised by advocates. Here is what the data actually shows. The SURMOUNT-1 trial, one of the most rigorous body composition studies of tirzepatide, assessed 160 participants with DXA scanning over 72 weeks. Tirzepatide produced an average total body weight reduction of 21.3%. Of that weight lost, approximately 75% was fat mass and 25% was lean mass (Look et al., Diabetes, Obesity and Metabolism, 2025). Lean mass fell by 10.9% in absolute terms. For semaglutide, a Canadian Family Physicians review summarising available trial data noted lean body mass loss comprising around 40% of total weight lost in some studies: a higher proportion than tirzepatide, though absolute lean mass losses were similar given semaglutide's lower total weight reduction (College of Family Physicians of Canada, PMC, 2025). A July 2025 systematic review in Pharmacological Research, drawing on PubMed and Embase literature through mid-2025, confirmed that GLP-1 receptor agonists consistently reduce skeletal muscle mass alongside fat mass, with lean mass loss of around 25% of total weight lost being the central tendency across studies (ScienceDirect, 2025). The Cell Reports Medicine study published in March 2026 added important nuance: in both obese mice and a proof-of-concept human trial, GLP-1 medicines predominantly reduced body fat, and while absolute muscle mass and strength decreased, relative muscle mass and strength (as a proportion of body weight) actually improved, resulting in better functional performance. That is an important distinction. Losing some absolute muscle mass during substantial weight loss is not inherently pathological. The concern is when lean mass loss is disproportionate, or when the client exits treatment weaker and less functional than they entered it.

The Role of Resistance Training: What the Evidence Shows

This is where the strength coach's role becomes not just useful but essential. The Frontiers in Clinical Diabetes and Healthcare mini-review (November 2025), a targeted literature search across PubMed/MEDLINE and Scopus, concluded clearly: combining GLP-1 receptor agonists with structured lifestyle changes, especially increased protein intake and strength training, can mitigate muscle loss and enhance overall outcomes. The most directly applicable clinical data comes from a prospective 6-month study of 200 adults with overweight or obesity who received education on resistance training and individualised protein intake at the point of initiating semaglutide or tirzepatide. At six months, participants had lost approximately 13% of body weight but only around 3% of muscle mass: a substantially better muscle preservation ratio than trials without structured exercise intervention, where lean mass loss typically comprises 25–40% of weight lost. Participants were instructed to aim for resistance training three times per week, with protein intake individualised but generally above the UK/international Dietary Reference Intake of 0.8 g/kg (Peralta-Reich, Medscape, April 2025). The mechanism makes physiological sense: resistance training provides the anabolic stimulus (mechanical loading) that tells skeletal muscle there is a reason to maintain its mass despite the caloric deficit created by appetite suppression. Without that signal, the body has no reason to preferentially retain muscle when shedding weight. A 2025 case series in SAGE Open Medicine described three patients using semaglutide or tirzepatide who engaged in resistance training 3–5 days per week and consumed protein at 0.73–1.04 g/lb of fat-free mass. Their lean soft tissue changes were −6.9%, +2.5%, and +5.8% respectively: across total weight losses of 13–33%. The sample is small and causation cannot be established from a case series, but the results illustrate what is achievable when resistance training and protein are genuinely prioritised alongside medication.

Protein: The Most Underaddressed Variable

The appetite suppression produced by GLP-1 medications is their primary mechanism; they work by slowing gastric emptying and acting on hypothalamic satiety centres. For weight loss, that is the point. The problem is that strong appetite suppression, if unmanaged, tends to reduce protein intake alongside total caloric intake. When protein drops below maintenance levels during a caloric deficit, muscle protein breakdown accelerates. The body cannot distinguish between deliberately restricting protein and accidentally restricting it: it responds the same way. Clinical reviews published in 2025 and 2026 (Barana et al., Nutrients 2025; Spreckley et al., Obesity Reviews 2026, as cited in clinical nutrition literature) have proposed a target of 1.5 g of protein per kilogram of fat-free mass daily for clients on GLP-1 therapy: notably higher than standard guidance. The more widely cited evidence-based range across reviews is 1.2–1.6 g/kg of total body weight per day, distributed across meals to support muscle protein synthesis at each eating occasion. In practical terms, a 90kg client on semaglutide should be targeting 108–144g of protein daily minimum, across three or four meals. Given that their appetite is substantially suppressed, achieving this without active effort and coaching is unlikely. This is where the coach's role in nutrition oversight becomes directly protective of the training outcome.

What Happens When Clients Stop

One dimension of GLP-1 therapy that strength coaches should understand is what happens at cessation. The STEP 1 extension trial data showed that participants who stopped semaglutide after 68 weeks regained approximately two-thirds of their lost weight within the following year. Weight regain after stopping GLP-1 therapy is common and rapid without maintenance of lifestyle changes. The Frontiers review noted that long-term weight maintenance is more successful when exercise is included: because exercise preserves the metabolic and musculoskeletal adaptations that reduce weight regain risk. Clients who have built genuine strength and muscle mass during GLP-1 therapy are better positioned for cessation than those who relied on medication alone. Muscle tissue is metabolically active: it increases resting energy expenditure and improves insulin sensitivity. A client who exits GLP-1 therapy with more muscle than they started with is physiologically better equipped to maintain their weight loss. That is the case for strength training during GLP-1 therapy in one sentence.

Practical Programming Considerations

A few specifics that are worth knowing when programming for clients on GLP-1 medications. First, energy availability is genuinely reduced, not just calorically but subjectively. Clients on these medications often report lower training energy, particularly in the first few months. Adjusting volume downward during the early titration period (typically the first 8–12 weeks as dose is escalated) is sensible rather than pushing for personal records during the phase of highest appetite suppression and lowest energy availability. Second, session pacing may need to change. GLP-1 medications slow gastric emptying, which affects how quickly pre-workout nutrition is available. Clients who eat close to sessions may feel nauseous or simply underperform. Some clients do better training in a semi-fasted state on these medications; others need to experiment with meal timing and size relative to sessions. Ask rather than assume. Third, the exercise selection priority should shift toward compound, multi-joint resistance training, squats, deadlift variations, pressing, pulling, hinge patterns, rather than high-volume isolated work. The goal is to provide the maximal anabolic stimulus with the available energy. A LEAN-PREP RCT currently recruiting (ClinicalTrials.gov NCT06885736, 6-month four-arm trial: control, resistance exercise, protein, resistance exercise + protein) will provide cleaner prospective data on these questions. It's worth watching for results in 2026–2027. Finally, check-in frequency matters more during GLP-1 therapy, not less. Body composition is changing faster than in typical coaching contexts; early identification of disproportionate muscle loss (declining strength-to-weight ratio, significantly reduced performance at similar RPE) allows coaching adjustments before the deficit becomes significant.

The Broader Point

GLP-1 medications are genuinely effective at producing weight loss. The trial data on that is unambiguous. What they do not do is produce fit, strong, metabolically healthy people automatically. The medication handles appetite and fat mobilisation. The strength coach handles the adaptation that determines what the client's body looks like, functions like, and is capable of after the weight is gone. That has always been the argument for strength training during weight loss. GLP-1 therapy makes it more urgent, not less.

FAQ